Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: Results of a randomized trial

Amedeo Mugellini, Jurij Dobovisek, Danijel Planinc, Giovanni Cremonesi, Roberto Fogari

Research output: Contribution to journalArticle

Abstract

The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)

Original languageEnglish
Pages (from-to)1419-1426
Number of pages8
JournalClinical Therapeutics
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

manidipine
Enalapril
Hydrochlorothiazide
Blood Pressure
Safety
Angiotensin-Converting Enzyme Inhibitors
Calcium Channel Blockers
Diuretics
Antihypertensive Agents
Placebos
Hypertension
delapril
Essential Hypertension

Keywords

  • antihypertensive treatment
  • delapril
  • enalapril
  • essential hypertension
  • hydrochlorothiazide
  • manidipine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension : Results of a randomized trial. / Mugellini, Amedeo; Dobovisek, Jurij; Planinc, Danijel; Cremonesi, Giovanni; Fogari, Roberto.

In: Clinical Therapeutics, Vol. 26, No. 9, 09.2004, p. 1419-1426.

Research output: Contribution to journalArticle

@article{d2ad1b32281d4cd688cb6082c3b32e32,
title = "Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: Results of a randomized trial",
abstract = "The use of coombination therapy is required to achieve blood pressure targets in 40{\%} to 75{\%} of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)",
keywords = "antihypertensive treatment, delapril, enalapril, essential hypertension, hydrochlorothiazide, manidipine",
author = "Amedeo Mugellini and Jurij Dobovisek and Danijel Planinc and Giovanni Cremonesi and Roberto Fogari",
year = "2004",
month = "9",
doi = "10.1016/j.clinthera.2004.09.018",
language = "English",
volume = "26",
pages = "1419--1426",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension

T2 - Results of a randomized trial

AU - Mugellini, Amedeo

AU - Dobovisek, Jurij

AU - Planinc, Danijel

AU - Cremonesi, Giovanni

AU - Fogari, Roberto

PY - 2004/9

Y1 - 2004/9

N2 - The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)

AB - The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 mg and the calcium channel antagonist manidipine 10 mg with those of a standard combination of another ACE inhibitor and a diuretic. The aim of this study was to compare the antihypertensive efficacy and tolerability of delapril 30 mg given alone or with manidipine 10 mg with those of enalapril 20 mg given alone or with hydrochlorothiazide (HCTZ) 12.5 mg in patients with mild to moderate essential hypertension. This was a multicenter, active-controlled, parallel-group trial. After an initial 2-week placebo run-in period, patients aged 18 to 75 years with diastolic blood pressure (DBP)

KW - antihypertensive treatment

KW - delapril

KW - enalapril

KW - essential hypertension

KW - hydrochlorothiazide

KW - manidipine

UR - http://www.scopus.com/inward/record.url?scp=9744279749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9744279749&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2004.09.018

DO - 10.1016/j.clinthera.2004.09.018

M3 - Article

C2 - 15531004

AN - SCOPUS:9744279749

VL - 26

SP - 1419

EP - 1426

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 9

ER -